Dog allergen-specific Immunoglobulin E (Dog-specific IgE)

Dog allergen-specific Immunoglobulin E (IgE) refers to the subset of antibodies produced by the immune system that specifically recognize proteins found in dog dander, saliva, and urine, such as Can f 1 through Can f 6 [PMID: 26073116]. These antibodies circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils [PMID: 21457342]. When a sensitized individual is exposed to dog allergens, the allergens cross-link the IgE molecules on these effector cells, triggering the immediate release of inflammatory mediators like histamine, proteases, and leukotrienes. This biological cascade is the hallmark of Type I hypersensitivity and results in clinical symptoms of dog allergy, including rhinoconjunctivitis and asthma. Therapeutic interventions target this pathway by either neutralizing circulating IgE to prevent receptor binding or by using allergen-specific immunotherapy to modulate the immune response toward tolerance. Monoclonal antibodies like Omalizumab are used to reduce the levels of free IgE, thereby downregulating the expression of FcεRI on effector cells [StatPearls: NBK545184]. This target is central to the diagnosis and management of pet-related allergic diseases.

Other names

Anti-dog IgECanis familiaris allergen-specific IgEDog-specific IgE antibodiesDog dander-specific IgE

Monoclonal antibodies like Omalizumab bind to the Fc region of free Immunoglobulin E, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils [StatPearls: NBK545184]. Allergen-specific immunotherapy (AIT) works by gradually desensitizing the immune system, shifting the response from IgE-mediated to IgG4-mediated and inducing regulatory T cells [PMID: 28341103].